known to cardiologists, are: (i) blockers of the renin -angiotensin system [angiotensin-converting enzyme (ACE) inhibitors or angiotensin II type I receptor blockers (ARBs)]; (ii) beta-adrenergic blockers; (iii) aldosterone antagonists; (iv) implantation of cardioverterdefibrillators; and (v) the application of cardiac resynchronization therapy in patients with QRS prolongation. Each has been shown to reduce mortality in patients with heart failure. As a consequence, the cumulative benefits of these therapies has improved the prognosis in these patients quite substantially. 3 The development of a management plan for individual patients with heart failure (as is the case with many conditions) requires an assessment of prognosis. This has been a challenging task in patients with chronic heart failure. A number of risk scores have been established since 2003 to aid physicians in this task. 4 These scores have been of varying size and clinical value. In a very ambitious and far-reaching effort, Pocock and colleagues have formed the Meta-analysis Global Group in Chronic Heart Failure (MAGICC). They now report an analysis of individual data on almost 40 000 patients with chronic heart failure enrolled into 30 cohort studies, six of which were clinical trials and the remainder registries. 4 These patients were followed for a median of 2.5 years, providing almost 100 000 patient-years of observation, with almost 16 000 deaths! Certainly, this represents the largest number of patients and deaths ever investigated in heart failure. Among these 30 cohorts, the seven largest cohorts contributed 78% of the patients (and deaths) to this meta-analysis (see supplementary table S1 in Pocock et al.
5,6
The third limitation is the considerable amount of missing data. Only two of the 13 variables that were entered into the modelage and gender-were available in all patients. Five variables (body mass index, systolic pressure, chronic obstructive pulmonary disease, creatinine, and heart failure duration) were each missing in . 10 000 patients; and three others were not available in between 6500 and 10 000 patients. The fourth is the authors' statement that there were 'substantial between-study differences in mortality risk not explained by predictors in our model'. They thought that these differences 'may be due to geographic variation or unidentified patient selection criteria varying across the cohorts'. Despite the extensive statistical gymnastics, including 'sophisticated computer-intensive multiple imputation methods', that were performed, it may require true MAGICC to deal with these problems, especially in the absence of external validation of the risk score (which the authors felt was unnecessary).
The last, and probably the most serious, limitation is that of the five above-mentioned guideline Class IA indications for the treatment of heart failure, only one-blockade of the renin-angiotensin system-was utilized in two-thirds of the patients with reduced ejection fraction which were entered into the seven largest cohorts. The use of beta-blockers ranged from 0% in the largest trial, the DIG trial, conducted before the widespread use of these agents in prolonging life in patients with chronic heart failure, 7 to 5 -55% of patients entered into the other six large
cohorts. An aldosterone antagonist was administered in only four of the seven largest cohorts (to between 13% and 50% of the patients) and apparently not at all in the other three cohorts, which were conducted before the routine use of these agents for the treatment of heart failure was advocated. Even in the small minority of patients in whom these three life-prolonging drugs were used, it is not known whether the doses were adequate. Furthermore, there is no mention in Pocock's paper, or the papers describing the individual cohorts, that any patients received devices-implanted cardioverter-defibrillators or cardiac resynchronization pacemakers-despite the well-established lifeprolonging effects of these therapies. Again, these cohorts were studied before these important therapies came into general use. In short, it does not appear that the patients entered into this meta-analysis received what would be considered to be optimal current guideline-approved therapy. For decades, there were few improvements in the treatment of chronic heart failure, and a risk score having the sophistication and size of the MAGICC score might easily have stood the test of time.
Fortunately, the care of patients with chronic heart failure and reduced ejection fraction, while still far from ideal, is at last improving. Therefore, the creation of an instrument to estimate risk in future patients presenting with chronic heart failure in a field that is as dynamic as this one is quite challenging. Such a score that is based on observations in patients receiving what would be considered to be inadequate therapy by contemporary standards, and that does not consider a key prognostic measure that is widely used, is analogous to trying to discern the road ahead by peering through a rear view mirror.
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